- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941843
Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal Cancer (LF-FOLFOX)
The Probability of a Protective Effect of Lactoferrin on FOLFOX-Related Toxicities in Colorectal Cancer
This randomized controlled clinical trial aims to investigate the potential protective effects of oral lactoferrin supplementation against chemotherapy-related toxicities in patients with colorectal cancer receiving the FOLFOX regimen.
A total of 44 eligible adult patients will be randomly allocated into two parallel groups (22 patients per group). The control group will receive standard FOLFOX chemotherapy, while the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin (Pravotin) at a dose of 100 mg twice daily, starting from the first chemotherapy cycle and continuing throughout the planned chemotherapy course.
The study will evaluate peripheral neuropathy, gastrointestinal and hematological toxicities, oxidative stress and neuroprotective biomarkers.
Study Overview
Status
Intervention / Treatment
Detailed Description
Colorectal cancer is commonly treated with oxaliplatin-based chemotherapy regimens such as FOLFOX, which combines oxaliplatin, 5-fluorouracil, and leucovorin. Despite its therapeutic effectiveness, FOLFOX is associated with peripheral neuropathy, gastrointestinal toxicity, hematological abnormalities, and impaired quality of life.
Lactoferrin is an iron-binding glycoprotein with antioxidant, anti-inflammatory, immunomodulatory, and potential neuroprotective properties. These biological activities may help mitigate chemotherapy-induced toxicities.
This study will investigate the potential protective effects of lactoferrin supplementation in 44 patients with histologically confirmed colorectal cancer who are scheduled to receive at least six cycles of FOLFOX chemotherapy at Damanhour Oncology Center.
Eligible participants will be randomly assigned in a 1:1 ratio to receive either standard FOLFOX chemotherapy alone or standard FOLFOX chemotherapy combined with oral lactoferrin 100 mg twice daily.
Participants will undergo clinical evaluations, laboratory monitoring, and assessment of chemotherapy-related adverse events. Laboratory investigations will include complete blood count, kidney and liver function tests, and serum biomarkers including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and malondialdehyde (MDA).
Clinical assessments and laboratory investigations will be conducted during chemotherapy, with final assessments at the completion of the planned chemotherapy course.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Toka M El-Banna, Clinical pharmacy TA
- Phone Number: 00201018546392
- Email: tokaelbanna@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients aged 18 years or older with histologically confirmed colorectal cancer.
- Patients scheduled to receive at least six cycles of FOLFOX chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Exclusion Criteria:
- Pre-existing peripheral neuropathy of grade 1 or higher.
- Hereditary neuromuscular disorders.
- Advanced liver disease, defined as liver enzymes greater than three times the upper limit of normal or established cirrhosis.
- Chronic kidney disease with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m².
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard FOLFOX Chemotherapy
Participants assigned to the control group will receive standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin according to the routine oncology treatment protocol. |
Standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin, administered according to the treating oncology center's standard protocol. |
|
Experimental: FOLFOX Plus Lactoferrin
Participants assigned to the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin supplementation (Pravotin) at a dose of 100 mg twice daily, initiated at the first chemotherapy cycle and continued throughout the planned chemotherapy course. |
Standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin, administered according to the treating oncology center's standard protocol. Oral lactoferrin supplementation (Lactomash), administered at a dose of 100 mg twice daily (total daily dose: 200 mg), starting from the first FOLFOX chemotherapy cycle and continuing throughout the planned chemotherapy course. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Oxaliplatin-Induced Peripheral Neuropathy
Time Frame: From baseline before initiation of FOLFOX therapy to 3 months after initiation of FOLFOX therapy.
|
Proportion of participants developing peripheral neuropathy during FOLFOX chemotherapy, assessed and graded according to biomarkers. |
From baseline before initiation of FOLFOX therapy to 3 months after initiation of FOLFOX therapy.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- - Macciò A, et al. The Oncologist. 2010
- Lesser GJ, Irby MB, Taylor RC, Snavely A, Case D, Wang A, Dietrich A, Duncan S. Lactoferrin supplementation for taste and smell abnormalities among patients receiving cancer chemotherapy. Support Care Cancer. 2022 Mar;30(3):2017-2025. doi: 10.1007/s00520-021-06609-8. Epub 2021 Oct 13.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Intestinal Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colonic Diseases
- Colorectal Neoplasms
- Amino Acids, Peptides, and Proteins
- Proteins
- Carbohydrates
- Hydrolases
- Enzymes
- Enzymes and Coenzymes
- Globulins
- Glycoproteins
- Glycoconjugates
- Endopeptidases
- Peptide Hydrolases
- Serine Endopeptidases
- Serine Proteases
- Dietary Proteins
- Milk Proteins
- Animal Proteins, Dietary
- Carrier Proteins
- Transferrins
- Iron-Binding Proteins
- Lactoglobulins
- Whey Proteins
- Metalloproteins
- Lactoferrin
- Folfox protocol
Other Study ID Numbers
- LF-FOLFOX-CRC-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data (IPD) will not be shared.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.